目的 探討金水寶片聯(lián)合吸入用復(fù)方異丙托溴銨溶液治療慢性阻塞性肺疾病的療效。方法 收集2022年2月—2024年1月就診宜興市人民醫(yī)院的79例慢性阻塞性肺疾病患者資料，按隨機(jī)數(shù)字表法將患者分為對(duì)照組（40例）和治療組（39例）。對(duì)照組使用吸入用復(fù)方異丙托溴銨溶液，2噴/次，4次/d。治療組在對(duì)照組基礎(chǔ)上口服金水寶片，4片/次，3次/d。治療2周后統(tǒng)計(jì)治療效果。對(duì)比兩組的治療效果、癥狀緩解時(shí)間、病情程度、肺功能指標(biāo)和血清指標(biāo)水平。結(jié)果 治療組的總有效率為94.87%，對(duì)照組的總有效率為80.00%，組間的比較差異有統(tǒng)計(jì)學(xué)意義（P＜0.05）。治療組患者喘息、胸悶、肺啰音、咯痰緩解時(shí)間均短于對(duì)照組（P＜0.05）。治療后，兩組的慢性阻塞性肺病評(píng)估測(cè)試（CAT）評(píng)分均顯著降低（P＜0.05），且治療組CAT評(píng)分較對(duì)照組更低（P＜0.05）。治療后，兩組用力肺活量（FVC）/第一秒用力呼氣容積（FEV₁）、最大通氣量（MVV）、呼氣峰值流量（PEF）均顯著升高（P＜0.05），且治療組FVC/FEV₁、MVV、PEF較對(duì)照組更高（P＜0.05）。治療后，兩組的血清Clara細(xì)胞分泌蛋白-16（CC-16）、白細(xì)胞介素-17A（IL-17A）、基質(zhì)金屬蛋白酶-9（MMP-9）水平顯著降低（P＜0.05）；治療組的血清CC-16、IL-17A、MMP-9水平低于對(duì)照組（P＜0.05）。結(jié)論 金水寶片聯(lián)合吸入用復(fù)方異丙托溴銨溶液可提高慢性阻塞性肺疾病的臨床療效，改善臨床癥狀和肺功能，控制病情發(fā)展，減輕炎癥反應(yīng)。

Objective To investigate the efficacy of Jinshuibao Tablets combined with Compound Ipratropium Bromide Solution for inhalation in treatment of chronic obstructive pulmonary disease. Methods 79 Patients with chronic obstructive pulmonary disease who visited Yixing People’s Hospital from February 2022 to January 2024, and divide them into a control group (40 cases) and a treatment group (39 cases) using a random number table method. Patients in control group received Compound Ipratropium Bromide Solution for inhalation, 2 sprays/time, 4 times daily. Patients in the treatment group was given Jinshui Bao Tablets orally on the basis of control group, 4 tablets/time, 3 times daily. Patients in both groups were evaluated after 2 weeks of treatment. The therapeutic effect, symptom remission time, disease degree, lung function index, and serum index were compared between two groups. Results The total effective rate of the treatment group (94.87%) was higher than that of the control group (80.00%), and there was a significant difference between the groups (P < 0.05). The relief time of wheezing, chest tightness, pulmonary rales, and sputum in the treatment group was lower than that in the control group (P < 0.05). After treatment, CAT scores in both groups were lower than those before treatment, and CAT score of the treatment group was lower than that of the control group (P < 0.05). After treatment, FVC/FEV₁, MVV, and PEF of both groups were higher than those before treatment (P < 0.05), and FVC/FEV₁, MVV, and PEF of the treatment group was higher than those of the control group (P < 0.05). After treatment, the serum levels of CC-16, IL-17A, and MMP-9 were significantly decreased in both groups (P < 0.05). The serum levels of CC-16, IL-17A, and MMP-9 in the treatment group were lower than those in the control group after treatment (P < 0.05). Conclusion Jinshuibao Tablets combined with Compound Ipratropium Bromide Solution for inhalation can improve the efficacy of COPD, enhance symptom improvement efficiency, control disease progression, improve lung function, alleviate inflammatory reactions.

R974

無(wú)錫市衛(wèi)生健康委科研項(xiàng)目(Z202220)